KLHL22 维持 PD-1 内稳态并防止 T 细胞过度抑制。
KLHL22 maintains PD-1 homeostasis and prevents excessive T cell suppression.
机构信息
Department of Radiation Medicine, Institute of Systems Biomedicine, School of Basic Medical Sciences, Peking University Health Science Center, 100191 Beijing, China.
Department of Gastroenterological Surgery, Laboratory of Surgical Oncology, Beijing Key Laboratory of Colorectal Cancer Diagnosis and Treatment Research, Peking University People's Hospital, 100044 Beijing, China.
出版信息
Proc Natl Acad Sci U S A. 2020 Nov 10;117(45):28239-28250. doi: 10.1073/pnas.2004570117. Epub 2020 Oct 27.
Aberrant programmed cell death protein 1 (PD-1) expression on the surface of T cells is known to inhibit T cell effector activity and to play a pivotal role in tumor immune escape; thus, maintaining an appropriate level of PD-1 expression is of great significance. We identified KLHL22, an adaptor of the Cul3-based E3 ligase, as a major PD-1-associated protein that mediates the degradation of PD-1 before its transport to the cell surface. KLHL22 deficiency leads to overaccumulation of PD-1, which represses the antitumor response of T cells and promotes tumor progression. Importantly, KLHL22 was markedly decreased in tumor-infiltrating T cells from colorectal cancer patients. Meanwhile, treatment with 5-fluorouracil (5-FU) could increase PD-1 expression by inhibiting the transcription of KLHL22. These findings reveal that KLHL22 plays a crucial role in preventing excessive T cell suppression by maintaining PD-1 expression homeostasis and suggest the therapeutic potential of 5-FU in combination with anti-PD-1 in colorectal cancer patients.
细胞程序性死亡蛋白 1(PD-1)在 T 细胞表面的异常表达被认为能抑制 T 细胞效应器活性,并在肿瘤免疫逃逸中发挥关键作用;因此,维持适当的 PD-1 表达水平具有重要意义。我们鉴定出 KLHL22 是 Cul3 基 E3 连接酶的衔接蛋白,它是一种主要的 PD-1 相关蛋白,能在 PD-1 被转运到细胞表面之前介导其降解。KLHL22 缺乏会导致 PD-1 的过度积累,从而抑制 T 细胞的抗肿瘤反应并促进肿瘤进展。重要的是,在结直肠癌患者的肿瘤浸润性 T 细胞中 KLHL22 的表达明显降低。同时,5-氟尿嘧啶(5-FU)治疗可通过抑制 KLHL22 的转录来增加 PD-1 的表达。这些发现表明 KLHL22 通过维持 PD-1 表达的平衡,在防止过度的 T 细胞抑制方面发挥着关键作用,并提示 5-FU 联合抗 PD-1 在结直肠癌患者中的治疗潜力。
相似文献
Proc Natl Acad Sci U S A. 2020-11-10
Cancer Immunol Res. 2018-9-18
引用本文的文献
Cell Insight. 2025-4-10
Exp Hematol Oncol. 2025-3-14
J Photochem Photobiol B. 2025-4
EMBO Mol Med. 2024-11
EMBO Rep. 2024-10
本文引用的文献
World J Gastroenterol. 2019-8-7
Trends Immunol. 2019-4-9
J Cell Physiol. 2019-2-19
Cancer Res. 2018-11-15